Sun Pharmaceutical Industries, country's largest drugmaker by market cap, is set to announce its results for the quarter ended December FY12 on Monday, February 13. The company's profit after tax is likely to shoot up 65% to Rs 576 crore from Rs 350 crore year-on-year.
Revenues are seen going up by 20% to Rs 1,917 crore from Rs 1,601 crore during the same period. EBITDA too is expected to move up by 60% to Rs 705 crore from Rs 440.5 crore YoY.
Operating profit margin is likely to be at 36.8% in the October-December quarter of FY12 as against 27.5% in a year ago quarter and 41% in the previous quarter.
On quarter-on-quarter basis, revenues are seen going up just by 2% while EBITDA is seen falling 10% and PAT by 3.5%. Highlights
- YoY revenue growth due to consolidation of Taro numbers
- Sequential growth in the US (Ex-Taro) to be fueled by old launches such as Diltiazem + Tramadol generic and Uraoxatral generic launched under shared exclusivity
- Domestic formulation growth to be 10%+ excluding discontinued crams business (in Q1FY12)
- Export formulation besides other than business expected to grow at 20%+
- Core EBITDA improvement due to better profitability at TARO
- Guidance of 28 to 30% YoY growth in FY12
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
